AMN Stock — Amn Healthcare Services Inc

Up next

Next earnings call

Feb 18, 2027 Est · unconfirmed · in 14 wks

Q3 2026 earnings call transcript

call held Nov 5, 2026

Play latest call

Latest documents

what the company just published, in one sentence each

2026

Nov 6

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Revenue rises 40% as labor disruption boosts results

AMN Healthcare Services, Inc. reported nine-month revenue of $2,768.9 million, up 40%, as nurse and allied solutions revenue rose 74% to $2,009.3 million on labor disruption activity. Third-quarter revenue increased 13% to $717.3 million, while gross profit rose 24% to $229.1 million.

Revenue $717.27M ▲ 13.0% Net income $33.39M ▲ 14.0% Diluted EPS $0.83 ▲ 9.2%

Read from the MD&A section

5 source passages

References in this Quarterly Report to “AMN Healthcare,” the “Company,” “we,” “us” and “our” refer to AMN Healthcare Services, Inc. and its wholly owned subsidiaries. Revenue increased 40% to $2,768.9 million for the nine months ended September 30, 2026 from $1,982.2 million for the same period in 2025, attributable to higher revenue in our nurse and allied solutions segment. Nurse and allied solutions segment revenue increased 74% to $2,009.3 million for the nine months ended September 30, 2026 from $1,156.6 million for the same period in 2025. Revenue increased 13% to $717.3 million for the three months ended September 30, 2026 from $634.5 million for the same period in 2025, attributable to higher revenue in our nurse and allied solutions segment. Gross profit increased 24% to $229.1 million for the three months ended September 30, 2026 from $184.4 million for the same period in 2025, representing gross margins of 31.9% and 29.1%, respectively. Open the document at this passage

Nov 5

Earnings call

Revenue rose 13%; Q4 outlook is $655 to $670 million

AMN Healthcare reported third-quarter revenue of $717 million, up 13% year-over-year, with a $51 million favorable reserve adjustment; fourth-quarter revenue is projected at $655 to $670 million.

4 source passages

Revenue of $717 million grew 13% year-over-year, or 6% excluding labor disruption activities. Third quarter results included a $51 million favorable reserve adjustment for past labor disruption events. Moving to the fourth quarter outlook, we expect consolidated revenue in the range of $655 to $670 million. Thank you for your interest in AMN Healthcare, and thank you to our clients, our clinicians, our team members, and suppliers who work tirelessly every day to ensure quality workforce outcomes and care are delivered. Open the document at this passage

Nov 5

Current report 8-K

Q3 revenue rose 13%, but Q4 sales outlook declines

AMN Healthcare Services, Inc. reported Q3 revenue of $717 million, up 13%, and adjusted EBITDA of $94 million, up 63%. Q4 revenue is guided to $655 - $670 million, or 10-12% lower year over year.

Financial results

5 source passages

AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its third quarter 2026 financial results. Consolidated revenue for the quarter was $717 million, a 13% increase from the prior year and a 7% increase from the prior quarter. Adjusted EBITDA was $94 million, a year-over-year increase of 63%. Consolidated revenue | $655 - $670 million Revenue in the fourth quarter of 2026 is expected to be 10-12% lower than the prior year. Open the document at this passage

Aug 7

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way

Revenue $673.24M ▲ 2.3% Net income $21.16M Diluted EPS $0.53

Aug 6

Earnings call

Q2 2026 earnings call AI summary on its way

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

View all 125 metrics

Revenue (TTM)

$3.52B

Trailing 12 months

Net income (TTM)

$109.02M

Trailing 12 months

Revenue growth YoY

+13.0%

Year over year

Operating margin

5.8%

Trailing 12 months

P / E (TTM)

13.8

Trailing earnings · reciprocal yield 7.3%

FCF yield

22.3%

TTM · current market cap

Return on invested capital

10.3%

Trailing 12 months

Net cash

−$487.39M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+3.8%

Year over year · more shares

Price change (1Y)

+136.6%

Trailing year

Short interest

11.1%

Latest settlement · 3.9 days to cover

View all 125 metrics

Quarterly results

Revenue Net income Net loss

▼10.2% $734.71M −$187.53M '24 Q4* ▼16% $689.53M −$1.09M '25 Q1 ▼11.1% $658.17M −$116.20M '25 Q2 ▼7.7% $634.50M $29.29M '25 Q3 ▲1.8% $748.23M −$7.70M '25 Q4* ▲99.9% $1.38B $62.17M '26 Q1 ▲2.3% $673.24M $21.16M '26 Q2 LATEST ▲13% $717.27M $33.39M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q3 FY26 earnings call · Nov 5, 2026

Q3 FY26

TL;DR. Q3 revenue and earnings exceeded guidance, nurse and allied demand strengthened, search grew 15%, and adjusted EBITDA rose 63%. Q4 revenue is expected to decline, while international staffing, language services pricing, locum tenens, and the Kaiser renewal present stated risks.

Bullish

+ Q3 revenue reached $717 million, up 13% year over year, while net income rose to $33 million.
+ Adjusted EBITDA increased 63% year over year to $94 million and adjusted EBITDA margin reached 13.0%.
+ Nurse and allied revenue reached $460 million with segment volume 16% higher than a year ago.
+ Search revenue grew 15% year over year, led by executive search and physician permanent placement.
+ International nurse revenue increased 32% year over year in the third quarter.
+ Some businesses are expected to return to growth during 2027.

Bearish

− Fourth-quarter revenue is expected to decline 10% to 12% year over year.
− Fourth-quarter nurse and allied revenue is expected to decline 13% to 15% year over year.
− Embassy visa appointment delays are expected to constrain international nurse placements in 2027.
− Language services pricing declined 9% year over year.
− Locum tenens revenue fell 5% year over year to $138 million.
− The Kaiser contract expires at the end of 2026 and is subject to a competitive RFP.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 19.3 · elevated Equity put/call 0.63

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +29%

above

Price vs 50-day avg −2%

below

RSI (14) 42

neutral

MACD trend Negative

52-week position 68%

mid-range

Volume (OBV) Bullish div.

accumulating

Momentum

relative strength

Strong

1-month return −6%

trailing

6-month return +40%

trailing

YTD return +141%

this year

Relative strength +39%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $39 › 200d $30 — 50d above 200d

Institutional flow Accumulating

271 of 289 funds reported for Sep 30 · net +804.8K sh shares · +49 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

11.07% of shares out · ▲ +11.5% MoM · 3.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

289 holders — mid 3-yr range

Squeeze score 68

elevated · 0–100

Fundamentals

Strong

Revenue growth +5%

Y/Y

Gross margin 39%

contracting

EPS growth +36%

Y/Y

Free cash flow $233.8M

Valuation P/E 13.8

below peers

Buyback $216.0M

remaining

Balance sheet $733.1M

net debt

Quant / Vol

risk profile

Very High

Volatility 70%

annualized · 1-yr

Max drawdown −26%

past year

ATR 6.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 8 of last 8

Latest guidance · from the Earnings Call filed Aug 6, 2026

Reported SG&A as a percent of revenue · third quarter 22% – 22.5%

Adjusted EBITDA margin · third quarter 6.5% – 7%

Cash and equivalents · third quarter at least $225M

Previous outlook earlier release · from the Earnings Call filed May 7, 2026

Still-open targets the latest release did not restate under the same label.

Consolidated revenue · second quarter $620M – $635M

Gross margin · second quarter 28% – 28.5%

SG&A as a percent of revenue · second quarter 23% – 23.5%

Adjusted EBITDA margin · second quarter 6.7% – 7.2%

Reported SG&A as a percent of revenue · second quarter 23% – 23.5%

Prior guidance period ended · from the Earnings Call filed Aug 6, 2026

Consolidated revenue · third quarter $640M – $655M

Gross margin · third quarter 27% – 27.5%

Reported SG&A · third quarter 22% – 22.5%

Operating margin · third quarter 0.2% – 0.8%

Nurse and allied segment revenue · third quarter 9% – 11%

Guided vs delivered · last 8 settled

Consolidated revenue third quarter

guided $640M – $655M

guided $640M – $655M $717.27M Beat +10.8%

Consolidated revenue first quarter of 2026

guided $1.23B – $1.24B

guided $1.23B – $1.24B $1.38B Beat +11.8%

Consolidated revenue fourth quarter of 2025

guided $715M – $730M

guided $715M – $730M $748.23M Beat +3.6%

Consolidated revenue third quarter of 2025

guided $610M – $625M

guided $610M – $625M $634.5M Beat +2.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+29% Bullish

Price vs 50-day avg

−2% Neutral

RSI (14)

42 Neutral

MACD trend

Negative Bearish

52-week position

68% Neutral

Volume (OBV)

Bullish div. Bullish

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $39 › 200d $30 — 50d above 200d

Institutional flow Accumulating

271 of 289 funds reported for Sep 30 · net +804.8K sh shares · +49 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

11.07% of shares out · ▲ +11.5% MoM · 3.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

289 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $15 Now $38 · 68% Range high $49

vs 200-day avg +29% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Medical Care Facilities — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
AMN Amn Healthcare Services Inc this stock	$1.47B	+141.2%	+4.5%	13.8	11.1%
HCA HCA Healthcare, Inc.	$104.25B	+6.9%	+7.1%	16.6	2.3%
FSNUY Fresenius SE & Co. KGaA	$33.34B	+3.3%	—	—	0.0%
THC Tenet Healthcare Corp	$22.76B	+43.9%	+0.9%	8.3	2.2%
EHC Encompass Health Corp	$13.83B	+32.8%	+10.5%	22.0	3.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

312

% held: 123.5%
Reported: 271 of 289
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

327

View

Short & Settlement

Short Interest Rising

Shares short

4.3M

Days to cover: 3.9d
Change: +439.3K sh

View

Short Volume

Short vol %

75%

As of: Nov 13, 2026

Short Total

View

Fails to Deliver

FTD shares

101

Value: $3.7K
As of: Oct 14, 2026

View

Off-Exchange

Off-exchange %

43.0%

Week of: Oct 5, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Buy

Member

Greg Gianforte

Amount: $15.0K–$50.0K
Traded: Nov 9, 2020

View

Financials

Revenue (FY)

$2.7B

Net income (FY): $-95.7M
EPS diluted: $-2.48

View

Buybacks

Authorized

$1.4B

Remaining: $216.0M

Spent Remaining

View

Filings

SEC Filings

Latest

10-Q

Filed: Nov 6, 2026
This year: 17

AMN Healthcare Services, Inc. reported nine-month revenue of $2,768.9 million, up 40%, as nurse and allied solutions revenue rose 74% to $2,009.3 million on labor disruption activity. Third-quarter revenue increased 13% to $717.3 million, while gross profit rose 24% to $229.1 million.

View

Proposed Sales

Value

$114.1K

Shares: 3.7K
Filed: Jun 15, 2026

View

Earnings & Events

Webcasts

Last webcast

Nov 5, 2026

View

	5D	20D	120D	MTD	YTD
AMN	+5.1%	-6.1%	+39.7%	-19.3%	+141.2%
SPY	+2.6%	-1.2%	+0.5%	-0.2%	+10.6%
vs SPY	+2.5%	-4.9%	+39.2%	-19.1%	+130.6%

AMN · Amn Healthcare Services Inc

Price & Indicators

Up next

Latest documents

Metrics snapshot

Quarterly results

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns